- Business Wire•18 hours agoAlnylam Reports Positive Interim Clinical Results for Fitusiran from Ongoing Phase 2 Open Label Extension Study in Patients with Hemophilia A or B without Inhibitors
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company today announced new positive results from its ongoing Phase 2 open-label extension study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia A or B without inhibitors.
- Business Wire•2 days agoAlnylam Reports Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced positive interim results from Part D of its ongoing Phase 1 study with fitusiran, an investigational RNAi therapeutic, in patients with hemophilia with inhibitors.
ALNY : Summary for Alnylam Pharmaceuticals, Inc. - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (ALNY)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||37.19 x 100|
|Ask||48.38 x 200|
|Day's Range||40.62 - 42.82|
|52 Week Range||31.38 - 105.84|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-9.15|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|